Dr. Öğr. Üyesi Tarık Ercan

Real-World Treatment Patterns and Safety Outcomes of Targeted Therapies in a Single-Center Chronic Lymphocytic Leukemia Cohort

Medicina, 2026

DOI 10.3390/medicina62040736 PMID 42075610 Açık erişimli tam metinKaynak: ORCID

Polycythemia Vera in Clinical Practice: A Single-Center Experience Focusing on Thrombotic Complications and Management Strategies

Indian Journal of Hematology and Blood Transfusion, 2026

DOI 10.1007/s12288-026-02400-z Kaynak: OpenAlex

Prediction of CD34+ hematopoietic stem cells in healthy allogeneic stem cell donors on the Optia cell separator based on CE2: Which formula is more correlated with actual CD34+?

Transfusion, 2024

DOI 10.1111/trf.17990 PMID 39152946 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients,Esansiyel Trombositemide CALR ve JAK2V617F Mutasyonlarının Klinik Seyir ve Hastalık Sonuçlarına Etkisi: Türk Hastalarda Geriye Dönük Çok Merkezli Çalışma

Turkish Journal of Hematology, 2024

DOI 10.4274/tjh.galenos.2024.2023.0430 PMID 38433449 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

PB2147: CLINICAL FACTORS DETERMINING THE SURVIVAL OF MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE: A SINGLE-CENTER EXPERIENCE

HemaSphere, 2023

DOI 10.1097/01.hs9.0000975348.60378.b8 Açık erişimli tam metinKaynak: OpenAlex

P-055 Clinical factors determining the survival of multiple myeloma patients with extramedullary disease: a single-center experience

Clinical Lymphoma Myeloma & Leukemia, 2023

DOI 10.1016/s2152-2650(23)01673-7 Kaynak: OpenAlex

Impact of autologous stem cell transplantation on survival outcomes in patients with peripheral T cell lymphoma.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2022

DOI 10.1016/j.transci.2022.103514 PMID 35934613 Kaynak: ORCID

Real-life ruxolitinib experience in intermediate-risk myelofibrosis.

Blood research, 2021

DOI 10.5045/br.2021.2021101 PMID 34916339 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

APLASTİK ANEMİ HASTALARINDA ELTROMBOPAG DENEYİMİ: TÜRKİYE ÇOK MERKEZLİ GERÇEK YAŞAM VERİSİ

Kocaeli Üniversitesi - AVESİS, 2021

Kaynak: OpenAlex

TEDAVİ NAİF VE NÜKS/REFRAKTER KLL HASTALARINDAOBİNİTUZUMAB DENEYİMİ: TÜRKİYE ÇOK MERKEZLİGERÇEK YAŞAM VERİSİ

Kocaeli Üniversitesi - AVESİS, 2021

Kaynak: OpenAlex

Hydroxychloroquine-Associated Thrombotic Thrombocytopenic Purpura

Turkish journal of haematology : official journal of Turkish Society of Haematology, 2020

DOI 10.4274/tjh.galenos.2020.2020.0322 PMID 32702948 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

PB1955 REAL LIFE DATA OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA RESISTANT OR INTOLERANT TO IMATINIB

HemaSphere, 2019

DOI 10.1097/01.hs9.0000566316.98256.dc 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

PB2235 SYMPTOM BURDEN AND SPLEEN SIZE RESPONSE WITH RUXOLUTINIB IN A REAL‐LIFE TURKISH COHORT

HemaSphere, 2019

DOI 10.1097/01.hs9.0000567416.09909.d5 Açık erişimli tam metinKaynak: OpenAlex

PS1433 RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE

HemaSphere, 2019

DOI 10.1097/01.hs9.0000564008.97747.a5 Açık erişimli tam metinKaynak: OpenAlex

TWEAK levels in patients with prediabetes and diabetes mellitus

Endocrine Abstracts, 2018

DOI 10.1530/endoabs.56.p377 Kaynak: OpenAlex

Utility of Peripheral Blood Parameters in Predicting Breast Cancer Risk

Asian Pacific Journal of Cancer Prevention, 2015

DOI 10.7314/apjcp.2015.16.6.2409 PMID 25824773 40 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex